Wealthfront’s iShares Biotechnology ETF IBB Stock Holding History

Wealthfront’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-51	Closed	-$5K	–	626
2015 Q3	$5K	Buy	51 +21	+70%	+$2.52K	﹤0.01%	1103
2015 Q2	$4K	Sell	30 -54	-64%	-$6.46K	﹤0.01%	1094
2015 Q1	$10K	Buy	+84	New	+$9.27K	﹤0.01%	635
2014 Q3	–	Sell	-45	Closed	-$4K	–	686
2014 Q2	$4K	Buy	+45	New	+$3.54K	﹤0.01%	543

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wealthfront's IBB Position: Q4 2015 in Review

Wealthfront sold out of iShares Biotechnology ETF (IBB) in Q4 2015, closing a stake of 51 shares — an estimated $5K sold.

Wealthfront first reported a position in IBB in Q2 2014 and held it in 4 quarters. The position peaked at $10K in Q1 2015. 432 funds tracked by Wall St. Rank hold IBB as of Q4 2015.

Wealthfront reported no remaining iShares Biotechnology ETF position as of Q4 2015 after selling out during the quarter.
Wealthfront sold 51 iShares Biotechnology ETF shares in Q4 2015, an estimated $5K.
Wealthfront first reported a position in iShares Biotechnology ETF in Q2 2014 and held it in 4 quarters.
Wealthfront's iShares Biotechnology ETF position peaked at $10K in Q1 2015.
432 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2015.

Based on Wealthfront's 13F filing for Q4 2015, filed 17 Feb 2016.